The Comprehensive Cancer Center of Metropolitan Detroit (CCCMD) received its initial core funding and designation by the Director of the National Cancer Institue in 1978. The CCCMD was established through the affiliation of the Michigan Cancer Foundation and the Wayne State University School of Medicine, for the propose of facilitating interdisciplinary and interdepartmental activities in cancer research and cancer care, to coordinate and integrate the cancer-related activities in its metropolitan region, and of supporting the augmentation of cancer resources in this area. Since formation of the CCCMD, emphasis has been placed on the initiation and support of multidisciplanary, interinstitutional, and broad-based projects and programs. The CCCMD core grant has provided the opportunity for the orderly acquisition of cancer research and resource facilities; superior staff development; establishment and sustenance of interinstitutional and interdepartmental cancer research collaborations; and overall enhancement of cancer research and care achievements in Detroit. The task of coordinating the collaborative and multi-interest programs described in this application falls to the leadership of the Center, the Director, the Associate Directors, and their staffs. Each Associate Director is responsible for the planning and initiation of broad-based programs; and the Center's Operating Committee, which includes the Center Director, is responsible for overall program planning, cross-disciplinary collaborations, and the identification of worthwhile development projects in all program areas. Renewal of this core grant is requested to sustain the work of the CCCMD.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA022453-13
Application #
3101677
Study Section
Special Emphasis Panel (SRC (15))
Project Start
1988-04-01
Project End
1992-03-31
Budget Start
1990-07-01
Budget End
1991-03-31
Support Year
13
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Wayne State University
Department
Type
Schools of Medicine
DUNS #
City
Detroit
State
MI
Country
United States
Zip Code
48202
Li, Feng; Wang, Yongli; Li, Dapeng et al. (2018) Perspectives on the recent developments with green tea polyphenols in drug discovery. Expert Opin Drug Discov 13:643-660
Ramseyer, Vanesa D; Kimler, Victoria A; Granneman, James G (2018) Vacuolar protein sorting 13C is a novel lipid droplet protein that inhibits lipolysis in brown adipocytes. Mol Metab 7:57-70
Healy, Mark A; Morris, Arden M; Abrahamse, Paul et al. (2018) The accuracy of chemotherapy ascertainment among colorectal cancer patients in the surveillance, epidemiology, and end results registry program. BMC Cancer 18:481
Lacher, Sarah E; Alazizi, Adnan; Wang, Xuting et al. (2018) A hypermorphic antioxidant response element is associated with increased MS4A6A expression and Alzheimer's disease. Redox Biol 14:686-693
Alsaab, Hashem O; Sau, Samaresh; Alzhrani, Rami M et al. (2018) Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages. Biomaterials 183:280-294
Chammaa, May; Malysa, Agnes; Redondo, Carlos et al. (2018) RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer. J Cell Physiol 233:9548-9562
Vaishampayan, Ulka N; Podgorski, Izabela; Heilbrun, Lance K et al. (2018) Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer. Clin Cancer Res :
Mills, Anne M; Peres, Lauren C; Meiss, Alice et al. (2018) Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES). Int J Gynecol Pathol :
Campbell, Douglas H; Lund, Maria E; Nocon, Aline L et al. (2018) Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer. PLoS One 13:e0196017
Sexton, Rachel E; Hachem, Ali H; Assi, Ali A et al. (2018) Metabotropic glutamate receptor-1 regulates inflammation in triple negative breast cancer. Sci Rep 8:16008

Showing the most recent 10 out of 826 publications